# Branched Stent Graft Market > Branched Stent Graft Market Research Report By Device Type (Aortic Branched Stent Grafts, Iliac Branched Stent Grafts, Femoral Branched Stent Grafts), By Material (Nitinol, Polytetrafluoroethylene (PTFE), Polyester), By Endovascular Access (Transfemoral, Transradial, Subclavian) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.98% - **2024:** $ 2.22 Billion - **2025:** $ 2.39 Billion - **2035:** $ 5.16 Billion - **Key Players:** Medtronic(US), Gore Medical (US), Cook Medical (US), Boston Scientific (US), Terumo Corporation (JP), Abbott Laboratories (US), B. Braun Melsungen AG (DE), JOTEC GmbH (DE) **Report ID:** MRFR/MED/29371-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/branched-stent-graft-market-31141 --- ## Market Summary ## **Branched Stent Graft Market Overview** As per MRFR analysis, the Branched Stent Graft Market Size was estimated at 2.22 (USD Billion) in 2024. The Branched Stent Graft Market Industry is expected to grow from 2.39 (USD Billion) in 2025 to 4.78 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 7.98% during the forecast period (2025 - 2034). ## **Key Branched Stent Graft Market Trends Highlighted** Key market drivers in the Branched Stent Graft market include the rising prevalence of aortic aneurysms and dissections, increasing adoption of minimally invasive endovascular procedures, advancements in technology leading to improved device designs, and expanding reimbursement coverage. This market presents significant growth opportunities as patient populations increase and innovative technologies emerge.Notable trends in recent times include the development of next-generation devices with enhanced flexibility, reduced profile, and improved durability.  The use of advanced imaging techniques and procedural planning tools is also gaining traction, enabling more precise and efficient interventions. Moreover, the growth of robotic-assisted procedures and the integration of artificial intelligence in stent graft design offer promising avenues for market expansion.Opportunities can be explored in the development of tailored devices for specific anatomical variations, addressing unmet clinical needs. Additionally, the expansion of markets in emerging economies and the increasing awareness of endovascular therapies among patients and healthcare providers present lucrative avenues for market penetration. Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Branched Stent Graft Market Drivers** ### **Rising Prevalence of Cardiovascular Diseases** Cardiovascular diseases, including heart attacks and strokes, are a major cause of mortality and morbidity worldwide. The increasing prevalence of these diseases is a key driver of the growth of the branched stent graft market. Branched stent grafts are used to treat aortic aneurysms, a condition in which the aorta, the body's largest artery, becomes enlarged and weakened. As the population ages, the incidence of aortic aneurysms is expected to increase, further driving the demand for branched stent grafts. The rising prevalence of cardiovascular diseases is attributed to several factors, including unhealthy lifestyles, such as smoking, unhealthy diet, and lack of physical activity. Additionally, the increasing prevalence of diabetes and obesity contributes to the development of cardiovascular diseases.  As a result, the demand for branched stent grafts is expected to increase in the coming years. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, accounting for an estimated 17.9 million deaths in 2019.The WHO projects that the number of deaths from cardiovascular diseases will continue to rise in the coming years, reaching 23.6 million by 2030. The increasing prevalence of cardiovascular diseases is a major concern for healthcare systems worldwide. Branched stent grafts offer a minimally invasive and effective treatment option for aortic aneurysms, which can help to improve patient outcomes and reduce the burden on healthcare systems. ### **Technological Advancements** The Branched Stent Graft Market Industry has witnessed significant technological advancements in recent years. These advancements have led to the development of more effective and less invasive branched stent grafts. For instance, the introduction of self-expanding branched stent grafts has eliminated the need for open surgery, which has reduced patient recovery time and improved outcomes. Additionally, advancements in imaging techniques, such as computed tomography (CT) and magnetic resonance imaging (MRI), have improved the accuracy of stent graft placement.This has led to better patient outcomes and reduced the risk of complications.  The continuous development of new and improved branched stent grafts is expected to drive the growth of the market in the coming years. Researchers are exploring the use of new materials and designs to improve the performance and durability of branched stent grafts. These advancements are expected to further expand the applications of branched stent grafts and improve patient outcomes. ### **Growing Awareness and Acceptance of Endovascular Procedures** Endovascular procedures are less invasive than traditional open surgery and offer several advantages, including reduced recovery time, less pain, and fewer complications. As a result, there has been a growing awareness and acceptance of endovascular procedures among both patients and physicians. Branched stent grafts are an important part of endovascular procedures used to treat aortic aneurysms. The increasing acceptance of endovascular procedures is expected to drive the demand for branched stent grafts in the coming years.  To promote awareness and acceptance of endovascular procedures, several initiatives have been undertaken by healthcare organizations and professional societies. These initiatives include educational campaigns, conferences, and workshops. The aim of these initiatives is to educate patients and physicians about the benefits of endovascular procedures and to encourage their use. ## **Branched Stent Graft Market Segment Insights** ### **Branched Stent Graft Market Device Type Insights** The Branched Stent Graft Market segmentation by Device Type can be divided into Aortic Branched Stent Grafts, Iliac Branched Stent Grafts, and Femoral Branched Stent Grafts. Among these, Aortic Branched Stent Grafts held the largest market share in 2023, and is expected to maintain its dominance throughout the forecast period. The growth of this segment can be attributed to the rising prevalence of aortic aneurysms and the increasing adoption of endovascular repair techniques. Iliac Branched Stent Grafts are expected to witness a significant growth rate during the forecast period.This growth can be attributed to the increasing number of minimally invasive procedures being performed for the treatment of iliac artery aneurysms and occlusive diseases. The growth of the market is attributed to the increasing prevalence of aortic aneurysms, iliac artery aneurysms, and peripheral artery disease, as well as the rising adoption of endovascular repair techniques. Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Branched Stent Graft Market Material Insights** The Branched Stent Graft Market is segmented based on material into Nitinol, Polytetrafluoroethylene (PTFE), and Polyester. In 2023, the Nitinol segment held the largest market share of around 65%, owing to its excellent biocompatibility, flexibility, and strength. It is used in the manufacturing of stents and stent grafts for the treatment of aortic aneurysms and dissections. The PTFE segment is expected to witness significant growth over the forecast period due to its high durability, low friction coefficient, and resistance to kinking.It is commonly used in the production of vascular grafts for peripheral artery disease and hemodialysis access. The Polyester segment is gaining traction in the market as it offers high tensile strength and resistance to tear. It is primarily used in the manufacturing of stent grafts for the treatment of abdominal aortic aneurysms. ### **Branched Stent Graft Market Endovascular Access Insights** The Branched Stent Graft Market is segmented based on endovascular access into Transfemoral, Transradial, and Subclavian. In 2023, the Transfemoral segment accounted for the largest share of the market, owing to its wide acceptance and established techniques. However, the Transradial segment is projected to grow at a higher CAGR during the forecast period, due to its advantages such as reduced bleeding complications and improved patient comfort. The Subclavian segment is expected to witness a steady growth, supported by the increasing adoption of minimally invasive endovascular procedures. ### **Branched Stent Graft Market Regional Insights** The regional segmentation of the Branched Stent Graft Market presents distinct market dynamics and growth opportunities. North America dominates the market with a significant share, driven by factors such as advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and favorable reimbursement policies. Europe follows closely, with a well-established healthcare system and a large patient population.  The Asia-Pacific (APAC) region is expected to witness substantial growth due to rising disposable incomes, increasing healthcare expenditure, and growing awareness about cardiovascular health.South America and the Middle East and Africa (MEA) regions offer emerging markets with untapped potential for market expansion. Overall, the Branched Stent Graft Market is witnessing robust growth, with key players focusing on strategic partnerships, product innovations, and geographical expansion to capitalize on these regional market opportunities. In 2024, the Branched Stent Graft Market revenue is projected to reach USD 2.1 billion, with a CAGR of 8.5% from 2024 to 2032. Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Branched Stent Graft Market Key Players And Competitive Insights** Major players in Branched Stent Graft Market industry are focused on developing innovative products and expanding their reach. Leading Branched Stent Graft Market players are investing heavily in research and development to introduce advanced products that meet the evolving needs of patients and healthcare providers. Partnerships and collaborations among industry participants are also driving Branched Stent Graft Market development, enabling the sharing of expertise and resources.  The Competitive Landscape of the Branched Stent Graft Market is characterized by intense competition among established players and emerging entrants. Top players are leveraging their strong distribution networks and brand recognition to maintain their market positions, while smaller companies are focusing on niche markets and cost-effective solutions to gain a competitive edge. Medtronic is a leading company in the Branched Stent Graft Market, offering a comprehensive portfolio of branched stent grafts for the treatment of complex aortic aneurysms. The company's Endurant II and Valiant Captivia Stent Grafts are widely recognized for their excellent clinical outcomes and durability. Medtronic's strong presence, established distribution channels, and commitment to innovation have contributed to its leadership position in the market.  The company is actively involved in research and development to enhance the performance and functionality of its products, ensuring its continued competitiveness in the face of evolving market dynamics.Boston Scientific is another prominent player in the Branched Stent Graft Market, known for its innovative product offerings and strong market presence.  The company's Zenith Alpha and Zenith TX2 Stent Grafts are highly regarded for their advanced features and versatility in treating complex aortic pathologies. Boston Scientific's commitment to clinical research and collaboration with leading medical centers has enabled it to develop differentiated products that meet the specific needs of patients. The company's extensive distribution network and established relationships with healthcare providers have been instrumental in its success in the Branched Stent Graft Market. **Key Companies in the Branched Stent Graft Market Include** ### Branched Stent Graft Market Industry Developments - **Q2 2024: Endologix Announces FDA Approval of DETOUR2 System for Treatment of Complex Peripheral Arterial Disease** Endologix received FDA approval for its DETOUR2 System, a device designed for complex peripheral arterial disease, which includes branched stent graft technology. The approval marks a significant regulatory milestone for the company in the U.S. market. - **Q1 2024: Cook Medical Launches Zenith Fenestrated+ Endovascular Graft in Europe** Cook Medical announced the commercial launch of its Zenith Fenestrated+ Endovascular Graft in select European markets. The device is designed for complex aortic aneurysms and features branched and fenestrated stent graft technology. - **Q2 2024: Terumo Aortic Receives CE Mark for RelayBranch Thoracic Stent-Graft System** Terumo Aortic obtained CE Mark approval for its RelayBranch Thoracic Stent-Graft System, enabling commercial sales in Europe. The device is intended for the treatment of aortic arch pathologies using branched stent graft technology. - **Q2 2024: Medtronic Announces First Patient Treated in U.S. Pivotal Study of Valiant TAAA Stent Graft System** Medtronic began its U.S. pivotal clinical trial for the Valiant TAAA Stent Graft System, a branched stent graft designed for thoracoabdominal aortic aneurysms. The first patient was successfully treated in the study. - **Q1 2024: Boston Scientific Completes Acquisition of Relievant Medsystems** Boston Scientific completed the acquisition of Relievant Medsystems, expanding its portfolio in minimally invasive vascular therapies, including branched stent graft solutions for complex aortic disease. - **Q2 2024: Terumo Aortic Opens New Manufacturing Facility in Scotland** Terumo Aortic inaugurated a new manufacturing facility in Scotland to increase production capacity for its branched and fenestrated stent grafts, supporting global demand and innovation. - **Q1 2024: Gore Medical Receives FDA Breakthrough Device Designation for New Branched Endoprosthesis** Gore Medical was granted FDA Breakthrough Device Designation for its new branched endoprosthesis, designed to treat complex aortic arch aneurysms with advanced stent graft technology. - **Q2 2024: Medtronic Launches Valiant Navion Thoracic Stent Graft in Japan** Medtronic launched the Valiant Navion Thoracic Stent Graft in Japan, expanding its global reach for branched stent graft solutions targeting thoracic aortic disease. - **Q1 2024: Endologix Announces Strategic Partnership with Artivion for Distribution of Branched Stent Grafts in Europe** Endologix entered into a strategic partnership with Artivion to distribute its branched stent graft products across European markets, aiming to enhance access to advanced endovascular solutions. - **Q2 2024: Cook Medical Receives FDA Approval for Zenith Branch Thoracoabdominal Endovascular Graft** Cook Medical received FDA approval for its Zenith Branch Thoracoabdominal Endovascular Graft, a device designed for the treatment of thoracoabdominal aortic aneurysms using branched stent graft technology. - **Q1 2024: Gore Medical Expands Manufacturing Operations in Arizona** Gore Medical expanded its manufacturing operations in Arizona to support increased production of its branched stent graft products, addressing rising global demand. - **Q2 2024: Boston Scientific Appoints New Head of Vascular Interventions Division** Boston Scientific appointed a new executive to lead its Vascular Interventions Division, which oversees the development and commercialization of branched stent graft technologies. ## **Branched Stent Graft Market Segmentation Insights** ## Market Drivers ### Technological Innovations in Stent Design Technological advancements in stent design and materials are significantly influencing the Branched Stent Graft Market. Innovations such as bioresorbable stents and improved delivery systems enhance the efficacy and safety of procedures. These developments not only improve patient outcomes but also reduce recovery times, making them more appealing to both patients and healthcare providers. The market is witnessing a shift towards more sophisticated stent designs that cater to specific anatomical challenges, thereby expanding the application range of branched stent grafts. This trend suggests a robust growth trajectory for the Branched Stent Graft Market as new technologies emerge. ### Increasing Prevalence of Vascular Diseases The rising incidence of vascular diseases, such as aortic aneurysms and peripheral artery disease, is a primary driver for the Branched Stent Graft Market. As populations age, the demand for effective treatment options increases. According to recent data, vascular diseases affect millions worldwide, leading to a surge in procedures requiring branched stent grafts. This trend is likely to continue, as healthcare providers seek innovative solutions to manage complex vascular conditions. The Branched Stent Graft Market is thus positioned to expand, driven by the need for advanced medical interventions that can address these growing health challenges. ### Growing Investment in Healthcare Infrastructure Investment in healthcare infrastructure is a crucial factor driving the Branched Stent Graft Market. As countries enhance their healthcare systems, there is a corresponding increase in the availability of advanced medical technologies, including branched stent grafts. Improved healthcare facilities and access to cutting-edge medical devices enable more patients to receive necessary treatments. This trend is particularly evident in emerging markets, where healthcare investments are rapidly increasing. Consequently, the Branched Stent Graft Market is poised for growth as healthcare systems evolve and expand, providing greater access to innovative treatment options. ### Regulatory Support for Advanced Medical Devices Regulatory bodies are increasingly supportive of innovations in medical devices, including branched stent grafts, which is a key driver for the Branched Stent Graft Market. Streamlined approval processes and guidelines for new technologies encourage manufacturers to invest in research and development. This regulatory environment fosters innovation, allowing for the introduction of safer and more effective stent grafts. As a result, the market is expected to see a rise in new product launches, enhancing competition and expanding the range of options available to healthcare providers. This supportive regulatory landscape is likely to propel the growth of the Branched Stent Graft Market. ### Rising Awareness and Acceptance of Minimally Invasive Techniques There is a growing awareness and acceptance of minimally invasive surgical techniques among both patients and healthcare professionals, which is propelling the Branched Stent Graft Market. Patients increasingly prefer procedures that promise shorter recovery times and reduced hospital stays. This shift in patient preference is supported by clinical evidence demonstrating the benefits of minimally invasive approaches. As a result, healthcare providers are adopting branched stent grafts more frequently, leading to an increase in procedures performed. The Branched Stent Graft Market is thus likely to benefit from this trend, as more patients seek out these advanced treatment options. ## Future Outlook The Branched Stent Graft Market is projected to grow at a 7.98% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of vascular diseases, and rising geriatric population. **New opportunities:** - Expansion into emerging markets with tailored products - - Development of biodegradable stent grafts for enhanced patient outcomes - Strategic partnerships with healthcare providers for integrated solutions By 2035, the Branched Stent Graft Market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Device Type: Aortic Branched Stent Grafts (Largest) vs. Iliac Branched Stent Grafts (Fastest-Growing) In the Branched Stent Graft Market, Aortic Branched Stent Grafts dominate the market share, owing to their essential role in treating complex aortic pathologies. This segment is preferred for its efficacy in achieving successful outcomes in patients with aortic aneurysms and dissections. On the other hand, Iliac Branched Stent Grafts are the fastest-growing segment, driven by increased incidences of peripheral artery disease and the rising demand for minimally invasive procedures. Aortic Branched Stent Grafts (Dominant) vs. Iliac Branched Stent Grafts (Emerging) Aortic Branched Stent Grafts lead in the market due to their widespread application in high-risk patients, offering robust solutions for aortic repair. Their dominance is sustained by ongoing advancements in technology, enhancing graft performance and patient recovery times. Conversely, Iliac Branched Stent Grafts are rapidly gaining traction. This segment's growth is fueled by an evolving landscape of vascular surgeries, with an emphasis on patient-centric approaches. Surgeons favor these grafts for addressing complex anatomical variations, leading to improved procedural success rates. The emergence of innovative designs tailored for iliac arteries further underscores this segment's rising significance. ### By Material: Nitinol (Largest) vs. Polytetrafluoroethylene (Fastest-Growing) In the Branched Stent Graft Market, the material segment is crucial for determining the effectiveness and reliability of the products. Nitinol leads the market share due to its excellent shape memory and flexibility, making it an ideal choice for complex vascular solutions. [Polytetrafluoroethylene](https://www.marketresearchfuture.com/reports/polytetrafluoroethylene-market-1740)(PTFE) follows, known for its biocompatibility, while Polyester is also significant but plays a less dominant role in this space. The growth potential varies significantly among these materials, with Nitinol commanding a substantial portion of demand due to its established reputation and performance in clinical applications. Material: Nitinol (Dominant) vs. Polyester (Emerging) Nitinol, a nickel-titanium alloy, is renowned for its unique properties, primarily its ability to recover its original shape when heated. This characteristic allows Nitinol stent grafts to navigate complex vascular structures effectively, providing a reliable solution in the Branched Stent Graft Market. Moreover, its fatigue resistance and biocompatibility reinforce its market position, making it the preferred material among surgeons. In contrast, Polyester, while emerging as a viable alternative, offers high tensile strength and good flow dynamics; however, it lacks the versatility of Nitinol. Polyester's market presence is growing due to its cost-effectiveness and suitability for less complex procedures, making it an appealing option in specific applications. ### By Endovascular Access: Transfemoral (Largest) vs. Transradial (Fastest-Growing) In the Branched Stent Graft Market, the endovascular access segment reveals distinct dynamics among three key pathways: transfemoral, transradial, and subclavian. The transfemoral approach holds the largest market share, favored for its ease of access and reliability in delivering stent grafts. Meanwhile, the transradial approach, although smaller in current share, shows significant promise due to its associated benefits, including reduced recovery time and lower complication rates compared to traditional access methods. The subclavian route remains relevant but has not gained the same traction as the other two methods. Transfemoral (Dominant) vs. Transradial (Emerging) The transfemoral access route continues to dominate the Branched Stent Graft Market, characterized by its well-established technique and broad acceptance among healthcare professionals. This method provides the necessary stability for complex procedures and supports a wide range of stent graft configurations. Conversely, the transradial approach is emerging as a viable alternative, particularly in light of growing interest in minimally invasive techniques. Its advantages, such as lower rates of bleeding complications and quicker patient mobilization, are driving increased adoption, making it a key area of focus for innovation and development in the market. ## Regional Market Share Analysis ### North America : Market Leader in Innovation North America is the largest market for branched stent grafts, accounting for approximately 45% of the global market share. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of vascular diseases, and a strong focus on research and development. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring the availability of innovative medical devices to meet rising demand. The United States is the primary contributor to this market, with key players such as Medtronic, Gore Medical, and Boston Scientific leading the competitive landscape. The presence of these established companies fosters innovation and enhances product offerings. Additionally, the growing adoption of minimally invasive procedures is expected to boost the demand for branched stent grafts, solidifying North America's position as a market leader. ### Europe : Emerging Regulatory Frameworks Europe is the second-largest market for branched stent grafts, holding approximately 30% of the global market share. The region's growth is propelled by an aging population, increasing awareness of vascular health, and supportive regulatory frameworks. The European Medicines Agency (EMA) plays a crucial role in ensuring the safety and efficacy of medical devices, which encourages innovation and market entry for new products. Leading countries in this region include Germany, France, and the UK, where significant investments in healthcare infrastructure and technology are evident. Key players like B. Braun Melsungen AG and JOTEC GmbH are actively involved in product development and market expansion. The competitive landscape is characterized by a mix of established companies and emerging startups, fostering a dynamic environment for growth and innovation. ### Asia-Pacific : Rapidly Growing Market Potential Asia-Pacific is rapidly emerging as a significant market for branched stent grafts, accounting for approximately 20% of the global market share. The region's growth is driven by increasing healthcare expenditure, rising prevalence of cardiovascular diseases, and a growing geriatric population. Additionally, government initiatives aimed at improving healthcare access and quality are expected to further stimulate market growth in the coming years. Countries like Japan, China, and India are at the forefront of this growth, with Japan being a leader in advanced medical technologies. The competitive landscape features both global players and local manufacturers, creating a diverse market environment. Companies such as Terumo Corporation and Abbott Laboratories are key contributors, focusing on innovation and expanding their product portfolios to meet the evolving needs of healthcare providers and patients. ### Middle East and Africa : Untapped Market Opportunities The Middle East and Africa region is gradually emerging in the branched stent graft market, holding approximately 5% of the global market share. The growth in this region is driven by increasing healthcare investments, rising awareness of vascular diseases, and improving healthcare infrastructure. Governments are focusing on enhancing medical services, which is expected to create new opportunities for market players in the coming years. Countries like South Africa and the UAE are leading the way in adopting advanced medical technologies. The competitive landscape is characterized by a mix of local and international players, with companies looking to establish a foothold in this growing market. As healthcare systems evolve, the demand for innovative medical devices, including branched stent grafts, is anticipated to rise significantly, presenting lucrative opportunities for stakeholders. ## Competitive Benchmarking The Branched Stent Graft Market is currently characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of vascular diseases. Key players such as Medtronic (US), Gore Medical (US), and Boston Scientific (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Medtronic (US) emphasizes innovation through continuous product development, focusing on minimally invasive solutions that cater to a growing patient demographic. Meanwhile, Gore Medical (US) leverages its strong reputation for quality and reliability, concentrating on expanding its product portfolio to include advanced graft technologies. Boston Scientific (US) appears to be pursuing aggressive regional expansion, particularly in emerging markets, thereby broadening its customer base and enhancing its competitive edge.The market structure is moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is particularly crucial in a market where timely delivery can significantly impact patient outcomes. The collective influence of these major companies shapes a competitive environment that encourages innovation while also fostering collaboration among industry players. In August Medtronic (US) announced the launch of its latest branched stent graft, which integrates advanced imaging technology to enhance procedural accuracy. This strategic move not only reinforces Medtronic's commitment to innovation but also positions the company to capture a larger share of the market by addressing the specific needs of vascular surgeons. The integration of imaging technology is likely to improve patient outcomes, thereby enhancing Medtronic's reputation in the industry. In July Gore Medical (US) expanded its manufacturing capabilities by opening a new facility in Europe, aimed at increasing production efficiency and meeting the rising demand for branched stent grafts. This expansion is strategically significant as it allows Gore to respond more swiftly to market needs while also reducing lead times for customers. Such operational enhancements are expected to solidify Gore's market position and improve its competitive stance against other players. In September Boston Scientific (US) entered into a strategic partnership with a leading telehealth provider to integrate remote monitoring capabilities into its branched stent graft offerings. This collaboration is indicative of a broader trend towards digitalization in the healthcare sector, allowing for improved patient management and follow-up care. By embracing telehealth solutions, Boston Scientific is likely to enhance its value proposition, making its products more appealing to healthcare providers. As of October the Branched Stent Graft Market is witnessing a shift towards digitalization, sustainability, and the integration of artificial intelligence in product development and patient care. Strategic alliances are increasingly shaping the competitive landscape, fostering innovation and collaboration among key players. The focus appears to be shifting from price-based competition to differentiation through technology, innovation, and supply chain reliability. This evolution suggests that companies that prioritize these aspects will likely emerge as leaders in the market, setting new standards for quality and patient care. ## Recent News & Developments - **Q2 2024: Endologix Announces FDA Approval of DETOUR2 System for Treatment of Complex Peripheral Arterial Disease** Endologix received FDA approval for its DETOUR2 System, a device designed for complex peripheral arterial disease, which includes branched stent graft technology. The approval marks a significant regulatory milestone for the company in the U.S. market. - **Q1 2024: Cook Medical Launches Zenith Fenestrated+ Endovascular Graft in Europe** Cook Medical announced the commercial launch of its Zenith Fenestrated+ Endovascular Graft in select European markets. The device is designed for complex aortic aneurysms and features branched and fenestrated stent graft technology. - **Q2 2024: Terumo Aortic Receives CE Mark for RelayBranch Thoracic Stent-Graft System** Terumo Aortic obtained CE Mark approval for its RelayBranch Thoracic Stent-Graft System, enabling commercial sales in Europe. The device is intended for the treatment of aortic arch pathologies using branched stent graft technology. - **Q2 2024: Medtronic Announces First Patient Treated in U.S. Pivotal Study of Valiant TAAA Stent Graft System** Medtronic began its U.S. pivotal clinical trial for the Valiant TAAA Stent Graft System, a branched stent graft designed for thoracoabdominal aortic aneurysms. The first patient was successfully treated in the study. - **Q1 2024: Boston Scientific Completes Acquisition of Relievant Medsystems** Boston Scientific completed the acquisition of Relievant Medsystems, expanding its portfolio in minimally invasive vascular therapies, including branched stent graft solutions for complex aortic disease. - **Q2 2024: Terumo Aortic Opens New Manufacturing Facility in Scotland** Terumo Aortic inaugurated a new manufacturing facility in Scotland to increase production capacity for its branched and fenestrated stent grafts, supporting global demand and innovation. - **Q1 2024: Gore Medical Receives FDA Breakthrough Device Designation for New Branched Endoprosthesis** Gore Medical was granted FDA Breakthrough Device Designation for its new branched endoprosthesis, designed to treat complex aortic arch aneurysms with advanced stent graft technology. - **Q2 2024: Medtronic Launches Valiant Navion Thoracic Stent Graft in Japan** Medtronic launched the Valiant Navion Thoracic Stent Graft in Japan, expanding its global reach for branched stent graft solutions targeting thoracic aortic disease. - **Q1 2024: Endologix Announces Strategic Partnership with Artivion for Distribution of Branched Stent Grafts in Europe** Endologix entered into a strategic partnership with Artivion to distribute its branched stent graft products across European markets, aiming to enhance access to advanced endovascular solutions. - **Q2 2024: Cook Medical Receives FDA Approval for Zenith Branch Thoracoabdominal Endovascular Graft** Cook Medical received FDA approval for its Zenith Branch Thoracoabdominal Endovascular Graft, a device designed for the treatment of thoracoabdominal aortic aneurysms using branched stent graft technology. - **Q1 2024: Gore Medical Expands Manufacturing Operations in Arizona** Gore Medical expanded its manufacturing operations in Arizona to support increased production of its branched stent graft products, addressing rising global demand. - **Q2 2024: Boston Scientific Appoints New Head of Vascular Interventions Division** Boston Scientific appointed a new executive to lead its Vascular Interventions Division, which oversees the development and commercialization of branched stent graft technologies. ## Report Scope | MARKET SIZE 2024 | 2.216(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 2.393(USD Billion) | | MARKET SIZE 2035 | 5.157(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.98% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Medtronic (US), Gore Medical (US), Cook Medical (US), Boston Scientific (US), Terumo Corporation (JP), Abbott Laboratories (US), B. Braun Melsungen AG (DE), JOTEC GmbH (DE) | | Segments Covered | Device Type, Material, Endovascular Access, Regional | | Key Market Opportunities | Advancements in minimally invasive techniques enhance growth potential in the Branched Stent Graft Market. | | Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the branched stent graft market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation of the Branched Stent Graft Market by 2035?** A: The Branched Stent Graft Market is projected to reach a valuation of 5.157 USD Billion by 2035. **Q: What was the market valuation of the Branched Stent Graft Market in 2024?** A: In 2024, the Branched Stent Graft Market was valued at 2.216 USD Billion. **Q: What is the expected CAGR for the Branched Stent Graft Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Branched Stent Graft Market during the forecast period 2025 - 2035 is 7.98%. **Q: Which company is a key player in the Branched Stent Graft Market?** A: Key players in the Branched Stent Graft Market include Medtronic, Gore Medical, and Cook Medical. **Q: What are the main device types in the Branched Stent Graft Market?** A: The main device types in the Branched Stent Graft Market include Aortic, Iliac, and Femoral Branched Stent Grafts. **Q: What was the valuation of Aortic Branched Stent Grafts in 2024?** A: The valuation of Aortic Branched Stent Grafts in 2024 was 0.887 USD Billion. **Q: What is the projected valuation for Iliac Branched Stent Grafts by 2035?** A: The projected valuation for Iliac Branched Stent Grafts by 2035 is 1.525 USD Billion. **Q: Which material segment is expected to grow the most in the Branched Stent Graft Market?** A: The Nitinol material segment is expected to grow significantly, with a valuation of 1.978 USD Billion by 2035. **Q: What endovascular access methods are utilized in the Branched Stent Graft Market?** A: The Branched Stent Graft Market utilizes endovascular access methods such as Transfemoral, Transradial, and Subclavian. **Q: What was the valuation of Femoral Branched Stent Grafts in 2024?** A: The valuation of Femoral Branched Stent Grafts in 2024 was 0.664 USD Billion. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/branched-stent-graft-market-31141*